Relationship between SGLT2 inhibitor use and specific cancer types: a systematic review and meta-analysis

Aim: The study aimed to explore the incidence of cancer as an adverse event to SGLT2 inhibitors (SGLT2i) use in Type 2 diabetes.Materials & methods: The study followed PRISMA guidelines to pool RCTs conforming the inclusion criteria. Random effects model was used to pool risk ratios.Results &...

Full description

Saved in:
Bibliographic Details
Main Authors: Muhammad Ishtiaq Obaid, Mohammad Saiem Shahzad, Fakhar Latif, Muhammad Hamza Khan, Moeez Akram, Syed Asad Mehdi Rizvi, Rana Muhammad Umer Nasrullah, Dayab Asad, Muhammad Adil Obaid
Format: Article
Language:English
Published: Taylor & Francis Group 2024-12-01
Series:Future Science OA
Subjects:
Online Access:https://www.tandfonline.com/doi/10.1080/20565623.2024.2400797
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1850099648594706432
author Muhammad Ishtiaq Obaid
Mohammad Saiem Shahzad
Fakhar Latif
Muhammad Hamza Khan
Moeez Akram
Syed Asad Mehdi Rizvi
Rana Muhammad Umer Nasrullah
Dayab Asad
Muhammad Adil Obaid
author_facet Muhammad Ishtiaq Obaid
Mohammad Saiem Shahzad
Fakhar Latif
Muhammad Hamza Khan
Moeez Akram
Syed Asad Mehdi Rizvi
Rana Muhammad Umer Nasrullah
Dayab Asad
Muhammad Adil Obaid
author_sort Muhammad Ishtiaq Obaid
collection DOAJ
description Aim: The study aimed to explore the incidence of cancer as an adverse event to SGLT2 inhibitors (SGLT2i) use in Type 2 diabetes.Materials & methods: The study followed PRISMA guidelines to pool RCTs conforming the inclusion criteria. Random effects model was used to pool risk ratios.Results & conclusion: After reviewing 19 studies, the analysis suggested a possible increased risk of reproductive, breast, thyroid, hematologic/lymphatic, urinary, skin and skeletal cancers with SGLT2i use. Conversely, lower incidences of respiratory and cardiovascular cancers were noted. However, these associations lacked statistical significance. Caution is advised in using SGLT2i due to potential cancer risks, especially in diabetic patients prone to cancer. More RCTs are essential due to limited research in this area.
format Article
id doaj-art-b48932bbb4824e998f9c9a9eb2a4ab67
institution DOAJ
issn 2056-5623
language English
publishDate 2024-12-01
publisher Taylor & Francis Group
record_format Article
series Future Science OA
spelling doaj-art-b48932bbb4824e998f9c9a9eb2a4ab672025-08-20T02:40:27ZengTaylor & Francis GroupFuture Science OA2056-56232024-12-0110110.1080/20565623.2024.2400797Relationship between SGLT2 inhibitor use and specific cancer types: a systematic review and meta-analysisMuhammad Ishtiaq Obaid0Mohammad Saiem Shahzad1Fakhar Latif2Muhammad Hamza Khan3Moeez Akram4Syed Asad Mehdi Rizvi5Rana Muhammad Umer Nasrullah6Dayab Asad7Muhammad Adil Obaid8Department of Medicine, Bahria University Medical & Dental College, Karachi, 74400, PakistanDepartment of Medicine, Bahria University Medical & Dental College, Karachi, 74400, PakistanDepartment of Medicine, Dow Medical College, Karachi, 74700, PakistanDepartment of Medicine, Karachi Medical & Dental College, Karachi, 74700, PakistanDepartment of Medicine, Allama Iqbal Medical College, Lahore, 54700, PakistanDepartment of Medicine, Jinnah Sindh Medical University, Karachi, 75510, PakistanDepartment of Medicine, Jinnah Sindh Medical University, Karachi, 75510, PakistanDepartment of Medicine, Jinnah Sindh Medical University, Karachi, 75510, PakistanDepartment of Medicine, Jinnah Sindh Medical University, Karachi, 75510, PakistanAim: The study aimed to explore the incidence of cancer as an adverse event to SGLT2 inhibitors (SGLT2i) use in Type 2 diabetes.Materials & methods: The study followed PRISMA guidelines to pool RCTs conforming the inclusion criteria. Random effects model was used to pool risk ratios.Results & conclusion: After reviewing 19 studies, the analysis suggested a possible increased risk of reproductive, breast, thyroid, hematologic/lymphatic, urinary, skin and skeletal cancers with SGLT2i use. Conversely, lower incidences of respiratory and cardiovascular cancers were noted. However, these associations lacked statistical significance. Caution is advised in using SGLT2i due to potential cancer risks, especially in diabetic patients prone to cancer. More RCTs are essential due to limited research in this area.https://www.tandfonline.com/doi/10.1080/20565623.2024.2400797antidiabetic medicationcancer incidencecancer riskdiabetes mellitusmalignancymeta-analysis
spellingShingle Muhammad Ishtiaq Obaid
Mohammad Saiem Shahzad
Fakhar Latif
Muhammad Hamza Khan
Moeez Akram
Syed Asad Mehdi Rizvi
Rana Muhammad Umer Nasrullah
Dayab Asad
Muhammad Adil Obaid
Relationship between SGLT2 inhibitor use and specific cancer types: a systematic review and meta-analysis
Future Science OA
antidiabetic medication
cancer incidence
cancer risk
diabetes mellitus
malignancy
meta-analysis
title Relationship between SGLT2 inhibitor use and specific cancer types: a systematic review and meta-analysis
title_full Relationship between SGLT2 inhibitor use and specific cancer types: a systematic review and meta-analysis
title_fullStr Relationship between SGLT2 inhibitor use and specific cancer types: a systematic review and meta-analysis
title_full_unstemmed Relationship between SGLT2 inhibitor use and specific cancer types: a systematic review and meta-analysis
title_short Relationship between SGLT2 inhibitor use and specific cancer types: a systematic review and meta-analysis
title_sort relationship between sglt2 inhibitor use and specific cancer types a systematic review and meta analysis
topic antidiabetic medication
cancer incidence
cancer risk
diabetes mellitus
malignancy
meta-analysis
url https://www.tandfonline.com/doi/10.1080/20565623.2024.2400797
work_keys_str_mv AT muhammadishtiaqobaid relationshipbetweensglt2inhibitoruseandspecificcancertypesasystematicreviewandmetaanalysis
AT mohammadsaiemshahzad relationshipbetweensglt2inhibitoruseandspecificcancertypesasystematicreviewandmetaanalysis
AT fakharlatif relationshipbetweensglt2inhibitoruseandspecificcancertypesasystematicreviewandmetaanalysis
AT muhammadhamzakhan relationshipbetweensglt2inhibitoruseandspecificcancertypesasystematicreviewandmetaanalysis
AT moeezakram relationshipbetweensglt2inhibitoruseandspecificcancertypesasystematicreviewandmetaanalysis
AT syedasadmehdirizvi relationshipbetweensglt2inhibitoruseandspecificcancertypesasystematicreviewandmetaanalysis
AT ranamuhammadumernasrullah relationshipbetweensglt2inhibitoruseandspecificcancertypesasystematicreviewandmetaanalysis
AT dayabasad relationshipbetweensglt2inhibitoruseandspecificcancertypesasystematicreviewandmetaanalysis
AT muhammadadilobaid relationshipbetweensglt2inhibitoruseandspecificcancertypesasystematicreviewandmetaanalysis